Alpha-GPC - ื”ืžืจื›ื™ื‘ ืฉืžื“ืขื ื™ื ื‘ื•ื—ืจื™ื ืœืคื•ืงื•ืก ื•ื–ื™ื›ืจื•ืŸ | ื”ืžื“ืจื™ืš ื”ืžืœื

Alpha-GPC ื”ื•ื ืžืงื•ืจ ื”ื›ื•ืœื™ืŸ ื”ื–ืžื™ืŸ ื‘ื™ื•ืชืจ ืœืชืื™ ื”ืžื•ื—. ื’ืœื” ืžื” ื”ืžื—ืงืจื™ื ื”ืงืœื™ื ื™ื™ื ืื•ืžืจื™ื, ืžื” ื”ืžื™ื ื•ืŸ ื”ื ื›ื•ืŸ ื•ืœืžื” 300 ืž"ื’ ื–ื” ื”ืžื™ื ื•ืŸ ืฉื ื—ืงืจ.

ย 

ืžืงื•ืจ ื”ื›ื•ืœื™ืŸ ืฉืžื“ืขื ื™ื ื‘ื•ื—ืจื™ื - ื•ืœืžื” 300 ืž"ื’ ื–ื” ื”ืžื™ื ื•ืŸ ืฉืžืฉื ื”

ื‘ืงืฆืจื”: Alpha-GPC ื”ื•ื ื”ืฆื•ืจื” ื”ื™ืขื™ืœื” ื‘ื™ื•ืชืจ ืฉืœ ื›ื•ืœื™ืŸ ืœืชืื™ ื”ืžื•ื—. ืžื—ืงืจื™ื ืงืœื™ื ื™ื™ื ืžืจืื™ื ืฉื”ื•ื ืชื•ืžืš ื‘ืจื™ื›ื•ื–, ื–ื™ื›ืจื•ืŸ ื•ืชืคืงื•ื“ ืงื•ื’ื ื™ื˜ื™ื‘ื™ โ€” ื•ืฉื”ืžื™ื ื•ืŸ 300 ืž"ื’ ื•ืžืขืœื” ื”ื•ื ื”ืกืฃ ืฉื ืžืฆื ื™ืขื™ืœ.

ืžื” ื–ื” Alpha-GPC ื•ืœืžื” ื”ื•ื ืฉื•ื ื”?

Alpha-GPC (Alpha-glycerophosphocholine) ื”ื•ื ืžืงื•ืจ ื›ื•ืœื™ืŸ ื‘ื™ื•-ื–ืžื™ืŸ ื‘ืžื™ื•ื—ื“. ื‘ื ื™ื’ื•ื“ ืœืžืงื•ืจื•ืช ื›ื•ืœื™ืŸ ืื—ืจื™ื ื›ืžื• Choline Bitartrate, Alpha-GPC ื—ื•ืฆื” ืืช ืžื—ืกื•ื ื“ื-ืžื•ื— ื‘ืงืœื•ืช ื™ื—ืกื™ืช ื•ืžื’ื™ืข ื™ืฉื™ืจื•ืช ืœืชืื™ ื”ืขืฆื‘.

ื”ื’ื•ืฃ ืžืฉืชืžืฉ ื‘ื›ื•ืœื™ืŸ ืœื™ื™ืฆื•ืจ ืืฆื˜ื™ืœื›ื•ืœื™ืŸ - ืžื•ืœื™ืš ืขืฆื‘ื™ ืงืจื™ื˜ื™ ื”ืžืขื•ืจื‘ ื‘:

  • ืจื™ื›ื•ื– ื•ืฉืžื™ืจืช ืงืฉื‘
  • ื–ื™ื›ืจื•ืŸ ืœื˜ื•ื•ื— ืงืฆืจ ื•ืืจื•ืš
  • ืžื”ื™ืจื•ืช ืขื™ื‘ื•ื“ ืžื™ื“ืข
  • ืชื™ืื•ื ืžื•ื˜ื•ืจื™ ื•ื™ื›ื•ืœืช ืœืžื™ื“ื”

ื”ืฉื•ื•ืื”: Alpha-GPC ืžื•ืœ ืžืงื•ืจื•ืช ื›ื•ืœื™ืŸ ืื—ืจื™ื

ืžืงื•ืจ ื›ื•ืœื™ืŸ % ื›ื•ืœื™ืŸ ื—ืฆื™ื™ืช ืžื—ืกื•ื ื“ื-ืžื•ื—
Alpha-GPC ~40% โญโญโญ ื’ื‘ื•ื”ื”
CDP-Choline (Citicoline) ~18% โญโญโญ ื’ื‘ื•ื”ื”
Phosphatidylcholine ~13% โญโญ ื‘ื™ื ื•ื ื™ืช
Choline Bitartrate ~41% โญ ื ืžื•ื›ื”

ืžื” ื”ืžื—ืงืจื™ื ืื•ืžืจื™ื?

๐Ÿ”ฌ De Jesus Moreno Moreno, 2003 (Clinical Therapeutics)

ืžื—ืงืจ ื›ืคื•ืœ-ืกืžื™ื•ืช ืขืœ 261 ื—ื•ืœื™ ืืœืฆื”ื™ื™ืžืจ ืงืœ ืขื“ ื‘ื™ื ื•ื ื™. ืงื‘ื•ืฆืช Alpha-GPC ื‘ืœื˜ื” ื‘ืฉื™ืคื•ืจ ืžื•ื‘ื”ืง ื‘ืฆื™ื•ื ื™ ADAS-Cog (ืกืงืœืช ื”ืขืจื›ื” ืงื•ื’ื ื™ื˜ื™ื‘ื™ืช) ืœืขื•ืžืช ืคืœืฆื‘ื• ืœืื—ืจ 6 ื—ื•ื“ืฉื™ื ืฉืœ ื˜ื™ืคื•ืœ.
PubMed PMID: 12814592

๐Ÿ”ฌ Bellar et al., 2015 (Journal of the International Society of Sports Nutrition)

ืžื—ืงืจ ืขืœ ืกืคื•ืจื˜ืื™ื ื‘ืจื™ืื™ื ืฉื ื˜ืœื• Alpha-GPC ืœืคื ื™ ืื™ืžื•ืŸ. ื ืžืฆืื” ืขืœื™ื™ื” ืžื•ื‘ื”ืงืช ื‘ืชืคื•ืงืช ื›ื•ื— ื•ืขืœื™ื™ื” ื‘-Growth Hormone ืœืื—ืจ ืฉื™ืžื•ืฉ. ืžืฆื‘ื™ืข ืขืœ ืืคืงื˜ ืœื ืจืง ืงื•ื’ื ื™ื˜ื™ื‘ื™ ืืœื ื’ื ืคื™ื–ื™.
PubMed PMID: 26175657

๐Ÿ”ฌ Kidd, 1998 (Alternative Medicine Review)

ืกืงื™ืจืช ืกืคืจื•ืช ืžืงื™ืคื” ืฉืกื™ื›ืžื” 13 ืžื—ืงืจื™ื ืงืœื™ื ื™ื™ื ืขืœ Alpha-GPC. ื”ืžืกืงื ื”: Alpha-GPC ืžืฆื™ื’ ืคืจื•ืคื™ืœ ื‘ื˜ื™ื—ื•ืช ื˜ื•ื‘ ื•ืชื•ืฆืื•ืช ืขืงื‘ื™ื•ืช ื‘ืชืžื™ื›ื” ื‘ื–ื™ื›ืจื•ืŸ ื•ื‘ืชืคืงื•ื“ ืงื•ื’ื ื™ื˜ื™ื‘ื™, ื‘ืžื™ื•ื—ื“ ื‘ืงืจื‘ ืžื‘ื•ื’ืจื™ื.

ืžื™ื ื•ืŸ: ืœืžื” 300 ืž"ื’ ื–ื” ื”ืกืฃ ืฉื ื—ืงืจ

ืžืจื‘ื™ืช ื”ืžื—ืงืจื™ื ื”ืงืœื™ื ื™ื™ื ื”ืžื•ืฆืœื—ื™ื ื”ืฉืชืžืฉื• ื‘ืžื™ื ื•ื ื™ื ืฉืœ 300-600 ืž"ื’ ืœื™ื•ื. ืžื™ื ื•ืŸ ืฉืœ 300 ืž"ื’ ื ื—ืฉื‘ ืœืžื™ื ื•ืŸ ื”ื‘ืกื™ืกื™ ื”ื™ืขื™ืœ.

โš ๏ธ ืฉื™ื ืœื‘: ืจื•ื‘ ื”ืชื•ืกืคื™ื ื”ื–ื•ืœื™ื ื‘ืฉื•ืง ืžื›ื™ืœื™ื 50-100 ืž"ื’ Alpha-GPC ื‘ืœื‘ื“ - ืžืชื—ืช ืœืกืฃ ืฉื ื—ืงืจ. ื‘ื“ื•ืง ืชืžื™ื“ ืืช ื”ืžื™ื ื•ืŸ ืฉื‘ืคื•ืขืœ.

ืžื™ ืขืฉื•ื™ ืœื”ืคื™ืง ืชื•ืขืœืช?

  • ๐Ÿ“š ืกื˜ื•ื“ื ื˜ื™ื - ืœืคื ื™ ื‘ื—ื™ื ื•ืช, ืœืฉื™ืคื•ืจ ื™ื›ื•ืœืช ืขื™ื‘ื•ื“ ื•ื–ื›ื™ืจืช ื—ื•ืžืจ
  • ๐Ÿ’ผ ืื ืฉื™ ืขืกืงื™ื ื•ื™ื–ืžื™ื - ืœืฉืžื™ืจืช ื—ื“ื•ืช ืžื—ืฉื‘ืชื™ืช ื‘ืขื•ืžืก ืขื‘ื•ื“ื” ื’ื‘ื•ื”
  • ๐Ÿง“ ืžื‘ื•ื’ืจื™ื ืžืขืœ 40 - ืœืชืžื™ื›ื” ื‘ื–ื™ื›ืจื•ืŸ ื•ื‘ืชืคืงื•ื“ ื™ื•ืžื™ื•ืžื™
  • ๐Ÿƒ ืกืคื•ืจื˜ืื™ื - ืœืฉื™ืคื•ืจ ืชื™ืื•ื ื•ื‘ื™ืฆื•ืขื™ื ืžื ื˜ืœื™ื™ื

ืฉืืœื•ืช ื ืคื•ืฆื•ืช

ืžื” ื”ื”ื‘ื“ืœ ื‘ื™ืŸ Alpha-GPC ืœื‘ื™ืŸ Citicoline?

ืฉื ื™ื”ื ืžืกืคืงื™ื ื›ื•ืœื™ืŸ ืœืชืื™ ื”ืžื•ื—, ืื‘ืœ ื‘ื“ืจื›ื™ื ืฉื•ื ื•ืช. Alpha-GPC ืžื›ื™ืœ ืื—ื•ื– ื›ื•ืœื™ืŸ ื’ื‘ื•ื” ื™ื•ืชืจ, ื‘ืขื•ื“ Citicoline ื’ื ืžืกืคืง cytidine ืฉืชื•ืจื ืœื™ื™ืฆื•ืจ CDP-choline. ื‘ืคื•ืจืžื•ืœื•ืช ืžืชืงื“ืžื•ืช ื ื™ืชืŸ ืœืžืฆื•ื ืฉื ื™ื”ื ื™ื—ื“.

ื”ืื ืืคืฉืจ ืœืฉืœื‘ Alpha-GPC ืขื ืชื•ืกืคื™ื ืื—ืจื™ื?

Alpha-GPC ื‘ืฉื™ืœื•ื‘ ืขื ืคื•ืกืคื˜ื™ื“ื™ืœืกืจื™ืŸ (SharpPSยฎ), Bacopa Monnieri ื•ื’ื™ื ืงื• ื‘ื™ืœื•ื‘ื”. ืฉื™ืœื•ื‘ื™ื ืืœื• ืžื•ืคื™ืขื™ื ื‘ืคื•ืจืžื•ืœื•ืช ืงื•ื’ื ื™ื˜ื™ื‘ื™ื•ืช ืžืชืงื“ืžื•ืช ื•ืžืจืื™ื ืกื™ื ืจื’ื™ื”.


* ื”ืžื™ื“ืข ื‘ืืชืจ ื–ื” ื”ื•ื ืœืžื˜ืจื•ืช ืžื™ื“ืข ื‘ืœื‘ื“ ื•ืื™ื ื• ืžื”ื•ื•ื” ื™ื™ืขื•ืฅ ืจืคื•ืื™. ืชื•ืกืคื™ ืชื–ื•ื ื” ืื™ื ื ืชืจื•ืคื•ืช ื•ืื™ื ื ืžื™ื•ืขื“ื™ื ืœืื‘ื—ืŸ, ืœืจืคื ืื• ืœืžื ื•ืข ืžื—ืœื” ื›ืœืฉื”ื™.

ืœืขื•ื“ ืžื™ื“ืข ืขืœ Think
ร—
ืœืขื•ื“ ืžื™ื“ืข ืขืœ Think ืœืขื•ื“ ืžื™ื“ืข ืขืœ Think

ืชื•ืกืฃ ืชื–ื•ื ื” ื”ืžืฉืœื‘ ื‘ืชื•ื›ื• ืืช ื›ืœืœ ืจื›ื™ื‘ื™ ื‘ื“ื’ืœ ื”ื ื—ืงืจื• ื‘ื”ืชืื ืœืฉื™ืคื•ืจ ืคื•ืงื•ืก, ื—ื“ื•ืช ื•ื–ื™ื›ืจื•ืŸ

ืชื•ืกืฃ ืชื–ื•ื ื” ื”ืžืฉืœื‘ ื‘ืชื•ื›ื• ืืช ื›ืœืœ ืจื›ื™ื‘ื™ ื‘ื“ื’ืœ ื”ื ื—ืงืจื• ื‘ื”ืชืื ืœืฉื™ืคื•ืจ ืคื•ืงื•ืก, ื—ื“ื•ืช ื•ื–ื™ื›ืจื•ืŸ